Specific Treatment exists for SARS-CoV-2 ARDS

Abstract

The clinician should consider Covid-19 patients increasing oxygen requirement from 6l/min to as high as 100% with high flow nasal cannula: dapsone administration. A Covid-19 committee at Hunt Regional Medical Center reviewed the first-period dapsone as an off-label medication. The hospital revalidated its effectiveness and reported furthermore, 44 (22/22) patients with ARDS at second period. ARDS onset was treated with dapsone: Decreased FIO2 in 7 patients and no worse in 1 patient. ARDS aggravated was treated: Decreased FIO2 in 6 patients and no worse in 3 patients. ARDS severe was no response in 2 patients. There are eight deaths in the twenty-onset group not treated with dapsone, but no death in the seventeen-onset group treated with dapsone at total period. There was a significant difference in ARDS treatment that results in the onset group. We clinically diagnosed a transient bulbar palsy associated with SARS-CoV-2 infection in ARDS onset group. We confirmed that dapsone treated the ARDS Onset by SARS-CoV-2 inflammasome clinically.

The Preventive and Treatment of the Neuro-Inflammasome in Sorokdo National Hospital

“…Soon Joe (09-12-1931 ~ 03-01-2021) contributed to making treatment method for MCI & AD, SARS-CoV-2 ARDS. So naming is Soon, Joe's treatment 31 . Dapsone may also be used to prevent, treat AD and COVID-19 ARDS 12,31 .…”

Death Toll by Dementia Drug

“…When a patient taking dapsone, mainly used in clinical studies on in ammasome competitors 19,55,72 , stopped it for stroke treatment and administered acetylcholine precursors for dementia care, the patient's courses were rapidly progressed to severe hypertension and neurologic abnormalities 54 .…”